Recall StatusOpen, Classified
Date Initiated2021-04-21
Product Quantity22550 units
Reason for Recall
Potential for the ADVIA Centaur Syphilis assay to carryover into other commercial assays. This carryover effect only occurs when the impacted assays are used immediately following testing with the Syphilis assay on the ADVIA Centaur XP/XPT or ADVIA Centaur CP systems
Firm Action
Siemens issued Urgent Medical Device Correction (UMDC) to US affected customers via FedEx beginning on 04/21/2021. An Urgent Field Safety Notice (UFSN) was issued to all OUS Siemens sites with affected customers electronically for distribution and regional reporting to their local
competent authorities beginning on 04/21/2021. Letter states reason for recall, health risk and Actions to be Taken by the Customer:
Please review this letter with your Medical Director.
If you have multiple ADVIA Centaur XP/XPT or ADVIA Centaur CP systems:
Siemens recommends testing the ADVIA Centaur Syphilis assay on a separate system from the impacted ADVIA Centaur assays (ADVIA Centaur PRGE, T4 on the ADVIA Centaur XP/XPT and ADVIA Centaur AFP, COR, PHTN, VALP on the ADVIA Centaur CP) to avoid the potential carryover effect.
If you have a single ADVIA Centaur XP/XPT or ADVIA Centaur CP system:
It is important to prevent the impacted assays from being processed after the
Syphilis assay without a Daily Cleaning Procedure (DCP) run in between. For
example, this can be achieved by processing all Syphilis testing, running the DCP, and then proceeding with all other testing including the impacted assays.
Complete and return the Field Correction Effectiveness Check Form attached to this letter within 30 days.
If you have received any complaints of illness or adverse events associated with the products listed in Table 1, immediately contact your local Siemens Healthineers Customer Care Center or your local Siemens Healthineers technical support representative.
Please retain this letter with your laboratory records and forward this letter to those who may have received this product.
Distribution Pattern
Worldwide distribution - US Nationwide distribution and the countries of Austria, Belgium, Burkina Faso, Croatia, Czech Republic, Egypt, Finland, France, Fren.Polynesia, Georgia, Germany, Germany, Greece, Guadeloupe, Italy, Kazakhstan, Latvia, Netherlands, Norway, Poland, Portugal, Qatar, Russian Fed., Serbia, Slovakia, Spain, Sweden, Switzerland, Turkey, U.A.E., Ukraine, United Kingdom.
Related FDA 510(k) Records
Devices referenced by this recall via K-numbers.
Official Source
View FDA Recall →Source: FDA Enforcement Report / Recall database. Always confirm against the official FDA record.